Abstract
Canine parvovirus type 2 (CPV-2) is responsible of acute hemorrhagic gastroenteritis in young dogs. CPV-2 emerged in 1978 in the USA, but new antigenic types, CPV-2a, 2b and 2c, have completely replaced the original type. In this study, we analyzed 81 animals collected in Sardinia, Italy. The VP2 sequence analysis of 27 positive samples showed that all antigenic CPV-2 types are circulating. CPV-2b seems to be the most widespread variant, followed by CPV-2a. Furthermore, 12 CPV-2b strains displayed further amino acid substitutions and formed a separate cluster in a phylogenetic tree, indicating regional genetic variation.
Avoid common mistakes on your manuscript.
Canine parvovirus type 2 (CPV-2) is a small, non-enveloped, single-stranded DNA virus with a diameter of 18 to 26 nm, belonging to the genus Protoparvovirus [10]. The genome is approximately 5.2 kb long and has two open reading frames (ORF), encoding two non-structural proteins (NS1, NS2) and two capsid proteins (VP1, VP2) [29]. The substitution of few amino acids in VP2, the main viral protein of the icosahedral capsid, alters relevant biological characteristics of the virus [25].
The virus, named CPV-2 to distinguish it from the antigenically unrelated minute virus of canines (MVC or CPV-1) [3, 23], spread in 1978 and caused epizootic gastroenteritis in dogs [6]. In 1979 and 1984, two new antigenic types, named CPV-2a and 2b, respectively, replaced the original CPV-2 worldwide [24, 26], gaining the ability to replicate efficiently in cats. The new antigenic types, CPV-2a and CPV-2b, differ from the original CPV-2 at least in five or six amino acids of the VP2 capsid protein. An additional amino acid change at position 297 (Ser → Ala), both in CPV-2a and CPV-2b, has lead to the designation “new CPV-2a” and “new CPV-2b” [10]. Moreover, in 2000 another antigenic variant, characterized by the amino acid substitution 426-Asp → Glu was reported [4]. This variant, designed CPV-2c, was subsequently reported all over the world [10] and has been associated with a severe clinical course with higher mortality rates [8]. The amino acids 426 and 297 of the VP2 are spatially close to residues 97 and 300, respectively, of the threefold spike domain on the capsid surface [15]. Structural studies have shown that this region interacts with the transferrin receptor (TFR) of the host cell to mediate infection, defines the host range, and is highly antigenic [1, 21, 22].
Most of the commercial vaccines currently available worldwide are based on CPV-2 or CPV-2b, and several studies have demonstrated that they are able to cross-protect against all four antigenic types, including the newly emerged CPV-2c [33].
The aim of the study was to characterize for the first time the CPV strains circulating in Sardinia (Italy), by molecular analysis. The partial VP2-encoding gene from 27 strains was amplified by PCR and sequenced. The characterization was performed by phylogenetic analysis of the sequences and amino acid composition of the different CPV-2 strains.
We analyzed 93 samples collected from 81 animals in the period 2005 to 2013, mainly in northern Sardinia. In detail, we analyzed 20 fecal samples from adult dogs with suspected parvovirosis, 55 samples (gut and mesenteric lymph nodes) collected from 12 adult cats and 43 dogs that had died from natural causes and did not have clinical signs of CPV, and 18 different tissue samples (gut, brain and spleen) collected from six carcasses of puppies with clinical signs of parvovirosis. DNA extraction was performed using a DNeasy Blood & Tissue Kit (QIAGEN), according to the manufacturer’s instructions. The presence of CPV-2 strains was detected using conventional polymerase chain reaction (cPCR) as described by Senda et al. [31]. To investigate the possible presence of viral coinfections, fecal and gut samples were also analyzed for the detection of canine or feline coronavirus (Cov) RNA as described previously [12], and brain and spleen samples were analyzed for the detection of canine distemper virus (CDV) RNA [14]. Characterization of viruses in the CPV-2-positive samples was performed by amplification and direct sequencing of the hypervariable region (611 bp long) of the gene encoding VP2, using primers Hfor and Hrev as described previously [4]. Our sequences were aligned using ClustalW software with canine parvovirus sequences retrieved from GenBank. Sequence translation and the phylogenetic analysis were performed using MEGA 6.0 software [34]. Phylogeny was estimated by the maximum likelihood (ML) algorithm with the HKY+I model. The reliability of the trees was calculated using 1000 bootstrap replicates. The evolutionary model that best fitted the data was selected using JmodelTest [28].
Out of 81 animals screened by conventional PCR assay, 27 (25 dogs and 2 cats) were positive for CPV-2 (31.4%). Five of the positive samples were fecal samples, and 22 were tissue samples. The sample identification number, source, host, and collection year are reported in Table 1. All samples tested PCR negative for CDV, and one gut sample tested COV positive. Five of the six puppies with clinical signs of parvovirosis tested CPV-2 positive in all of the tissues (gut, brain and spleen) analyzed, but only brain tissues were used for molecular characterization. Sequences of the CPV-2 positive samples were 99 to 100% identical to the VP2 sequences of other canine parvovirus strains available in GenBank. Our sequences were deposited in the GenBank database, with the accession numbers KM262057 to KM262083 (Table 1). Phylogenetic analysis revealed that all CPV variants are present in Sardinia (Fig. 1). Specifically, nine strains were identified as CPV-2a, 16 as CPV-2b, and two as CPV-2c. A amino acid sequence analysis (Table 1) showed that nine samples have Ala at aa position 297 and Asn at position 426, which is characteristic of new CPV-2a strains; 15 contained Ala at aa position 297 and Asp at position 426, which is characteristic of new CPV-2b; one had Ser at aa position 297 and Asp at position 426, which is characteristic of CPV-2b (Sar48), and two had Glu at aa position 426, which is characteristic of CPV-2c. The sequence of strain Sar9 contained the amino acid Lys instead of Asn at position 320. In addition, 12 of the 15 new CPV-2b isolates, including one from a cat, contained further amino acid substitutions, 371Ala→Gly and 418Ile → Thr. The strains Sar54 andSar55 also had a third amino acid substitution, 440Thr → Pro. In the phylogenetic tree, these strains formed a distinct cluster with good statistical support (bootstrap value, 87), together with the Italian strain KF373599, which was isolated in Sicily. Sar54 and Sar55 were detached from this cluster, forming a separate one. Out of two PCR-positive cats, one was infected by a new CPV-2a strain, and the other by a new CPV-2b strain.
Our data revealed that the new CPV-2b is the most widespread variant, followed by the new CPV-2a strain. The CPV-2c, despite being present in Sardinia since at least 2006 (Sar4), is the least common variant. This suggests that the CPV-2c strain has not spread at the same rate in Sardinia and has not taken over, even temporarily, as has been described for other geographical areas [9]. Only one sample contained the CPV-2b old variant (Ser297), but it was probably a new entry because the sample was collected in 2013 (Sar48). These data showed that all known variants are circulating in Sardinia. The prevalence of the new CPV-2b in Sardinia is in contrast with findings in other regions of Italy, where the prevalent strain is CPV-2c, followed by CPV-2a [7]. Phylogenetic analysis showed that the Sardinian strains were closely related to Italian isolates, with the exception of Sar1 and Sar5, which clustered with isolates from the USA and Portugal (Fig. 1), and Sar48, which was 100% identical to strain M74849 from the USA.
CPV has a worldwide distribution. CPV-2c has been found mainly in South American and European countries [19]. In Africa, the Middle East, Asia and Australia, CPV-2b and CPV-2a are the predominant variants, while CPV-2c seems to be absent [11, 13, 17, 32, 36, 37]. In Europe, there seems to be a more equal spreading of the three variants [10, 19], which could be related to geographical position and a different commercial flows of dogs. The 12 Sardinian CPV-2b strains, which formed a single separate clade in the phylogenetic tree, are characterized by the substitutions I418T and A371G, both of which are located in the GH insertion of VP2 [5]. This region includes the amino acids 267-498 between the βG and βH strands, is responsible for creating the 22-Å-long spikes around the icosahedral three-fold axes on the surface of the capsid, and shows the greatest variability among parvoviruses [5]. The I418T mutation was previously reported in both CPV-2a and CPV-2b isolates from Italy [2, 4, 8] and in CPV-2a isolates from Korea [16]. The A371G substitution, which is caused by a C → G transversion, is present in only one GenBank entry, the Italian sequence KF373599, for which there is no literature reference. In addition to the above-mentioned mutations, the strains Sar54 and Sar55 also displayed the substitution, T440P, which is caused by an A → C transversion. Position 440 is considered to be the main antigenic site of the virus, being located at the top of the threefold spike. Another mutation at this position, T440A, has been reported, detected for the first time in Italy by Battilani et al. [2] and also found in Korea [16], Uruguay [18], China [35] India [20] and Thailand [27]. The substitution T440P, detected in our strains, has never been reported so far. It is noteworthy that five of twelve samples belonging to this cluster were from brains of puppies with clinical signs of parvovirosis. As already reported, CPV can be detected in the brain in experimental and natural infections [9, 30]. The 12 CPV-2b strains account for about 44% of those examined, and they formed a separate cluster in the phylogenetic tree, indicating regional genetic variation of CPV-2 strains [17]. Our results showed that all currently known strains of CPV are circulating in northern Sardinia but that the new CPV-2b is the more widespread variant. However, because most of the samples were from northern Sardinia, the data do not necessarily reflect the overall distribution of CPV variants in Sardinia. Further extensive epidemiological investigation will be necessary to verify these results.
The finding of new or rare amino acid mutations confirms that this virus is continuously evolving. Although the available vaccines seem to cross-protect against all CPV-2 types, the spread of new variants could be responsible of immunity failure, underlining the need to carefully and constantly evaluate this virus through molecular epidemiology studies in order to prevent and control CPV-2 infection.
References
Allison AB, Organtini LJ, Zhang S, Hafenstein SL, Holmes EC, Parrish CR (2015) Single mutations in the VP2 300 loop region of the three-fold spike of the carnivore parvovirus capsid can determine host range. J Virol 90:753–767
Battilani M, Ciulli S, Tisato E, Prosperi S (2002) Genetic analysis of canine parvovirus isolates (CPV-2) from dogs in Italy. Virus Res 83:149–157
Binn LN, Lazar EC, Eddy GA, Kajima M (1970) Recovery and characterization of a minute virus of canines. Infect Immun 1:503–508
Buonavoglia C, Martella V, Pratelli A, Tempesta M, Cavalli A, Buonavoglia D, Bozzo G, Elia G, Decaro N, Carmichael L (2001) Evidence for evolution of canine parvovirus type 2 in Italy. J Gen Virol 82:3021–3025
Chapman MS, Rossmann MG (1993) Structure sequence and function correlations among parvoviruses. Virology 194:491–508
Cooper BJ, Carmichael LE, Appel MJ, Greisen H (1979) Canine viral enteritis II Morphologic lesions in naturally occurring parvovirus infection. Cornell Vet 69:134–144
Decaro N, Desario C, Addie DD, Martella V, Vieira MJ, Elia G, Zicola A, Davis C, Thompson G, Thiry E, Truyen U, Buonavoglia C (2007) Molecular epidemiology of canine parvovirus. Eur Emerg Infect Dis 13:1222–1224
Decaro N, Desario C, Parisi A, Martella V, Lorusso A, Miccolupo A, Mari V, Colaianni ML, Cavalli A, Di Trani L, Buonavoglia C (2009) Genetic analysis of canine parvovirus type 2c. Virology 385:5–10
Decaro N, Desario C, Amorisco F, Losurdo M, Colaianni ML, Greco MF, Buonavoglia C (2011) Canine parvovirus type 2c infection in a kitten associated with intracranial abscess and convulsions. J Feline Med Surg 13:231–236
Decaro N, Buonavoglia C (2012) Canine parvovirus a review of epidemiological and diagnostic aspects with emphasis on type 2c. Vet Microbiol 155:1–12
Doki M, Fujita K, Miura R, Yoneda M, Ishikawa Y, Taneno A, Kai C (2006) Sequence analysis of VP2 gene of canine parvovirus isolated from domestic dogs in Japan in 1999 and 2000. Comp Immunol Microbiol Infect Dis 29:199–206
Escutenaire S, Mohamed N, Isaksson M, Thoren P, Klingeborn B, Belak S, Berg M, Blomberg J (2007) Sybr Green real time reversetranscription-polymerase chain reaction assay for the generic detection of coronaviruses. Arch Virol 152:41–58
Firoozjaii H, Shoorijeh SJ, Mohammadi A, Tamadon A (2011) Characterization of Iranian isolates of canine parvovirus in fecal samples using polymerase chain reaction assay. Iran J Biotecnol 1:63–68
Frisk AL, König M, Moritz A, Baumgärtner W (1999) Detection of canine distemper virus nucleoprotein RNA by reverse transcription-PCR using serum whole blood and cerebrospinal fluid from dogs with distemper. J Clin Microbiol 11:3634–3643
Hueffer K, Parrish CR (2003) Parvovirus host range cell tropism and evolution. Curr Opin Microbiol 6:392–398
Kang BK, Song DS, Lee CS, Jung KI, Park SJ, Kim EM, Park BK (2008) Prevalence and genetic characterization of canine parvoviruses in Korea. Virus Genes 36:127–133
Kaur G, Chandra M, Dwivedi PN (2016) Phylogenetic analysis of VP2 gene of canine parvovirus and comparison with Indian and world isolates. Acta Virol 60:106–110
Maya L, Calleros L, Francia L, Hernández M, Iraola G, Panzera Y, Sosa K, Pérez R (2013) Phylodynamics analysis of canine parvovirus in Uruguay: evidence of two successive invasions by different variants. Arch Virol 158:1133–1141
Miranda C, Thompson G (2016) Canine parvovirus: the worldwide occurrence of antigenic variants. J Gen Virol 97:2043–2057
Mittal M, Chakravarti S, Mohapatra JK, Chug PK, Dubey R, Upmanuyu V, Narwal PS, Kumar A, Churamani CP, Kanwar NS (2014) Molecular typing of canine parvovirus strains circulating from 2008 to 2012 in an organized kennel in India reveals the possibility of vaccination failure. Infect Genet Evol 23:1–6
Parker JS, Murphy WJ, Wang D, O’Brien SJ, Parrish CR (2001) Canine and feline parvoviruses can use human or feline transferrin receptors to bind enter and infect cells. J Virol 75:3896–3902
Parker JS, Parrish CR (1997) Canine parvovirus host range is determined by the specific conformation of an additional region of the capsid. J Virol 71:9214–9222
Parrish CR (1999) Host range relationships and the evolution of canine parvovirus. Vet Microbiol 69:29–40
Parrish CR, Aquadro CF, Strassheim ML, Evermann JF, Sgro JY, Mohammed HO (1991) Rapid antigenic-type replacement and DNA sequence evolution of canine parvovirus. J Virol 65:6544–6552
Parrish CR, Carmichael LE (1986) Characterization and recombination mapping of an antigenic and host range mutation of canine parvovirus. Virology 148:121–132
Parrish CR, O’Connell PH, Evermann JF, Carmichael LE (1985) Natural variation of canine parvovirus. Science 230:1046–1048
Phromnoi S, Sirinarumitr K, Sirinarumitr T (2010) Sequence analysis of VP2 gene of canine parvovirus isolates in Thailand. Virus Genes 41:23–29
Posada D (2008) jModelTest: phylogenetic model averaging. Mol Biol Evol 25:1253–1256
Reed AP, Jones EV, Miller TJ (1988) Nucleotide sequence and genome organization of canine parvovirus. J Virol 62:266–276
Schaudien D, Polizopoulou Z, Koutinas A, Schwab S, Porombka D, Baumgärtner W, Herden C (2010) Leukoencephalopathy associated with parvovirus infection in Cretan hound puppies. J Clin Microbiol 48:3169–3175
Senda M, Parrish CR, Harasawa R, Gamoh K, Muramatsu M, Hirayama N, Itoh O (1995) Detection by PCR of wild-type canine parvovirus which contaminates dog vaccines. J Clin Microbiol 33:110–113
Soma T, Taharaguchi S, Ohinata T, Ishii H, Hara M (2013) Analysis of the VP2 protein gene of canine parvovirus strains from affected dogs in Japan. Res Vet Sci 94:368–371
Spibey N, Greenwood NM, Sutton D, Chalmers WS, Tarpey I (2008) Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Vet Microbiol 128:48–55
Tamura K, Stecher G, Peterson D, Filipski A, Kumar S (2013) MEGA6: molecular evolutionary genetics analysis version 60. Mol Biol Evol 30:2725–2729
Wang H, Jin H, Li Q, Zhao G, Cheng N, Feng N, Zheng X, Wang J, Zhao Y, Li L, Cao Z, Yan F, Wang L, Wang T, Gao Y, Yang S, Xia X (2016) Isolation and sequence analysis of the complete NS1 and VP2 genes of canine parvovirus from domestic dogs in 2013 and 2014 in China. Arch Virol 161:385–393
Wang HC, Chen WD, Lin SL, Chan JP, Wong ML (2005) Phylogenetic analysis of canine parvovirus VP2 gene in Taiwan. Virus Genes 31:171–174
Zourkas E, Ward MP, Kelman M (2015) Canine parvovirus in Australia: a comparative study of reported rural and urban cases. Vet Microbiol 181:198–203
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Dei Giudici, S., Cubeddu, T., Giagu, A. et al. First molecular characterization of canine parvovirus strains in Sardinia, Italy. Arch Virol 162, 3481–3486 (2017). https://doi.org/10.1007/s00705-017-3457-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00705-017-3457-3